These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39245907)

  • 1. Escherichia coli in the production of biopharmaceuticals.
    İncir İ; Kaplan Ö
    Biotechnol Appl Biochem; 2024 Sep; ():. PubMed ID: 39245907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escherichia coli as a versatile cell factory: Advances and challenges in recombinant protein production.
    İncir İ; Kaplan Ö
    Protein Expr Purif; 2024 Jul; 219():106463. PubMed ID: 38479588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives.
    Baeshen MN; Al-Hejin AM; Bora RS; Ahmed MM; Ramadan HA; Saini KS; Baeshen NA; Redwan EM
    J Microbiol Biotechnol; 2015 Jul; 25(7):953-62. PubMed ID: 25737124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current trends in biopharmaceuticals production in Escherichia coli.
    McElwain L; Phair K; Kealey C; Brady D
    Biotechnol Lett; 2022 Aug; 44(8):917-931. PubMed ID: 35796852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing recombinant protein production in Escherichia coli through metabolic and genetic engineering.
    Waegeman H; Soetaert W
    J Ind Microbiol Biotechnol; 2011 Dec; 38(12):1891-910. PubMed ID: 21901404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells.
    Berlec A; Strukelj B
    J Ind Microbiol Biotechnol; 2013 Apr; 40(3-4):257-74. PubMed ID: 23385853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modifications of the 5' region of the CASPON
    Köppl C; Buchinger W; Striedner G; Cserjan-Puschmann M
    Microb Cell Fact; 2024 Mar; 23(1):86. PubMed ID: 38509572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced technologies for improved expression of recombinant proteins in bacteria: perspectives and applications.
    Gupta SK; Shukla P
    Crit Rev Biotechnol; 2016 Dec; 36(6):1089-1098. PubMed ID: 26384140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic plants as factories for biopharmaceuticals.
    Giddings G; Allison G; Brooks D; Carter A
    Nat Biotechnol; 2000 Nov; 18(11):1151-5. PubMed ID: 11062432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceuticals from microorganisms: from production to purification.
    Jozala AF; Geraldes DC; Tundisi LL; Feitosa VA; Breyer CA; Cardoso SL; Mazzola PG; Oliveira-Nascimento L; Rangel-Yagui CO; Magalhães PO; Oliveira MA; Pessoa A
    Braz J Microbiol; 2016 Dec; 47 Suppl 1(Suppl 1):51-63. PubMed ID: 27838289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of biopharmaceutical proteins by yeast: advances through metabolic engineering.
    Nielsen J
    Bioengineered; 2013; 4(4):207-11. PubMed ID: 23147168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
    Ahmadpour S; Hosseinimehr SJ
    Curr Drug Deliv; 2018; 15(3):331-341. PubMed ID: 29165076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbial factories for recombinant pharmaceuticals.
    Ferrer-Miralles N; Domingo-Espín J; Corchero JL; Vázquez E; Villaverde A
    Microb Cell Fact; 2009 Mar; 8():17. PubMed ID: 19317892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein N-glycosylation in eukaryotic microalgae and its impact on the production of nuclear expressed biopharmaceuticals.
    Mathieu-Rivet E; Kiefer-Meyer MC; Vanier G; Ovide C; Burel C; Lerouge P; Bardor M
    Front Plant Sci; 2014; 5():359. PubMed ID: 25183966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial intelligence-driven systems engineering for next-generation plant-derived biopharmaceuticals.
    Parthiban S; Vijeesh T; Gayathri T; Shanmugaraj B; Sharma A; Sathishkumar R
    Front Plant Sci; 2023; 14():1252166. PubMed ID: 38034587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of three industrial Escherichia coli strains in fed-batch cultivations during high-level SOD protein production.
    Marisch K; Bayer K; Cserjan-Puschmann M; Luchner M; Striedner G
    Microb Cell Fact; 2013 Jun; 12():58. PubMed ID: 23758670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharmaceuticals derived from genetically modified plants.
    Goldstein DA; Thomas JA
    QJM; 2004 Nov; 97(11):705-16. PubMed ID: 15496527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.
    Huang CJ; Lin H; Yang X
    J Ind Microbiol Biotechnol; 2012 Mar; 39(3):383-99. PubMed ID: 22252444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.